Evidence map›Paper›PMID 39065571›Full record

ArticlePharmaceutics2024

A Second Wind for Inorganic APIs: Leishmanicidal and Antileukemic Activity of Hydrated Bismuth Oxide Nanoparticles.

Andriy Grafov, Ana Flávia da Silva Chagas, Alice de Freitas Gomes, Wessal Ouedrhiri, Pierfrancesco Cerruti, Maria Cristina Del Barone, Breno de Souza Mota, Carlos Eduardo de Castro Alves, Anny Maíza Vargas Brasil, Antonia Maria Ramos Franco Pereira and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andriy GrafovDepartment of Chemistry, University of Helsinki, A.I. Virtasen Aukio 1 (PL 55), 00560 Helsinki, Finland.ORCID 0000-0002-7387-3676
Ana Flávia da Silva ChagasMulti-User Center for Analysis of Biomedical Phenomena, State University of Amazonas, Manaus 69065-001, AM, Brazil.
Alice de Freitas GomesPost-Graduate Program in Hematology, The State University of Amazon, Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.
Wessal OuedrhiriDepartment of Chemistry, University of Helsinki, A.I. Virtasen Aukio 1 (PL 55), 00560 Helsinki, Finland.
Pierfrancesco CerrutiInstitute for Polymers, Composites, and Biomaterials, National Research Council, 80078 Pozzuoli, NA, Italy.ORCID 0000-0003-0822-2866
Maria Cristina Del BaroneInstitute for Polymers, Composites, and Biomaterials, National Research Council, 80078 Pozzuoli, NA, Italy.
Breno de Souza MotaSchool of Nursing, University of São Paulo, São Paulo 05403-000, SP, Brazil.
Carlos Eduardo de Castro AlvesLaboratory of Virology and Immunology, INPA, Manaus 69067-375, AM, Brazil.
Anny Maíza Vargas BrasilCoordination of Biomedicine, FAMETRO University Center, Manaus 69050-000, AM, Brazil.
Antonia Maria Ramos Franco PereiraLaboratory of Leishmaniasis and Chagas Disease, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil.
Gemilson Soares PontesPost-Graduate Program in Hematology, The State University of Amazon, Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.ORCID 0000-0001-9001-7954

Funding

European Comission Horizon 2020 MSCA-RISE-2016-734759, acronym VAHVISTUS
6 · The paper itself

Abstract

American cutaneous leishmaniasis is a disease caused by protozoa of the genus Leishmania. Currently, meglumine antimoniate is the first-choice treatment for the disease. The limited efficacy and high toxicity of the drug results in the necessity to search for new active principles. Nanotechnology is gaining importance in the field, since it can provide better efficacy and lower toxicity of the drugs. The present study aimed to synthesize, characterize, and evaluate the in vitro leishmanicidal and antileukemic activity of bismuth nanoparticles (BiNPs). Promastigotes and amastigotes of

Indexed as

anticancerbismuthleishmaniasismyeloid leukemiananoparticles

Identifiers

PMID39065571
PMCPMC11279939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.